EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L.
| Autor: | Breadner, D., Liu, G., Rothenstein, J., Wheatley-Price, P., Bains, P., Cheng, S., Wang, Y., Sun, S., Mithoowani, H., Juergens, R., Cheema, P., Vincent, M. |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2022 Supplement, Vol. 17 Issue 9, pS412-S413, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|